INTRODUCTION {#s1}
============

Cancer, which results from complex interactions between genetic and environmental factors, has become a challenging health problem. An increasing number of studies have been performed in the past few years to assess the relationship between genetic variation and cancer risk \[[@B1]\].

Oxygen (O~2~) concentration in tumor tissues is significantly lower than that in the surrounding normal tissues. Many studies have focused on hypoxia because of its function in maintaining tumor microenvironments \[[@B2]\]. Hypoxic tumor microenvironment initiates multiple cellular responses, such as proliferation and angiogenesis, triggering the development and progression of cancer. In general, hypoxia may regulate tumor cell phenotypes by altering genes that are sensitive to O~2~ pressure \[[@B3]\]. Studies have demonstrated that HIF-1 has an important function in the development and progression of cancer by activating various genes associated with angiogenesis, cell adhesion, erythropoiesis, and glucose transportation \[[@B4]\]. HIF-1 is a heterodimer consisting of an oxygen-sensitive subunit HIF-1α and a constitutively expressed subunit HIF-1β; it is degraded rapidly through the von Hippel--Lindau-mediated ubiquitin--proteasome pathway under normoxia conditions \[[@B5]\]. Recent studies have shown that HIF-1α is overexpressed in many human cancers with advanced tumor grade, suggesting that HIF-1α acts as an independent factor of cancer prognosis \[[@B6]\].

The human HIF-1α gene, which is located at chromosome 14q21--24, is composed of 15 exons. It codes for a 3919 bp cDNA and produces an 826 amino acid protein. Single nucleotide polymorphisms (SNPs) in coding regions can mediate amino acid changes and affect the structure and biological activity of the translated protein \[[@B7]\]. The most widely studied HIF-1α polymorphisms are 1772 C/T (Pro582Ser, rs11549465) and 1790 G/A (Ala588Thr, G1790A, rs11549467), which induce proline-to-serine and alanine-to-threonine amino acid substitutions, respectively. Both polymorphic variants can significantly elevate transcriptional activity than the wild type under both hypoxic and normoxic conditions in in vitro studies \[[@B8]\]. Moreover, both polymorphisms are associated with increased tumor microvessel density, thereby contributing to the development and progression of cancer \[[@B9]\].

HIF-1α 1772 C/T and 1790 G/A genetic polymorphisms were previously suggested to be responsible for the risk for various types of cancer. However, the results of epidemiological studies are inconsistent \[[@B10]--[@B12]\]. Thus, the relationship between HIF-1α polymorphisms and cancers requires further investigation. Accordingly, we performed a meta-analysis on eligible case--control studies to produce a more powerful estimation of the association of HIF-1α 1772 C/T and 1790 G/A polymorphisms with cancer risk.

Methods {#s2}
=======

Identification and eligibility of relevant studies {#s2.1}
--------------------------------------------------

All studies published before June 26, 2013 that investigated the association of HIF-1α 1772 C/T and 1790 G/A polymorphisms with cancer risk were considered in this meta-analysis. A systematic search of literature was carried out using PubMed and Embase. The keywords used for the search were "hypoxia-inducible factor-1" or "HIF-1" concatenated with "SNP," "polymorphism," "mutation," or "variant" and "tumor," "cancer," "carcinoma," or "malignancy." Only studies with complete data on the comparison of HIF-1α 1772 C/T or 1790 G/A polymorphisms between cancer patients and controls were selected. Case reports, animal studies, review articles, editorials, abstracts, reports with incomplete data, and studies based on pedigree data were excluded.

Data extraction {#s2.2}
---------------

Two investigators (Yang and Zhu) independently reviewed the articles to exclude irrelevant and overlapping studies. The results were compared, and disagreements were resolved by discussion and consensus. We only included the publication that reported the most extensive information when overlapping articles were found. The following data were extracted for each study: first author, year of publication, country, ethnicity, control source, cancer type, Hardy--Weinberg equilibrium, and the number of cases and controls for each genotype.

Statistical analysis {#s2.3}
--------------------

STATA (version 11.0; StataCorp, College Station, Texas, USA) was used for the meta-analysis. All genotype models for the two HIF-1α polymorphisms were evaluated. We also conducted subgroup analyses by cancer type, ethnicity, and source of control. For cancer type subgroups, we included the subgroup that contained more than three studies.

The existence of heterogeneity between studies was ascertained by Q-statistic. The pooled odds ratio (OR) was estimated with models based on fixed-effects or random-effects assumptions. A random-effects model was used when the significant Q statistic (*P* \< 0.1) indicated the presence of heterogeneity in the studies. Otherwise, a fixed-effects model was selected. The 95% confidence interval (CI) of OR was also calculated. The distribution of genotypes in the controls was checked for Hardy--Weinberg equilibrium. Studies with controls not in the Hardy--Weinberg equilibrium were subjected to sensitivity analysis.

The publication bias among the studies was assayed. Funnel plots of the HIF-1α 1772 C/T polymorphism for T allele versus C allele and the HIF-1α 1790 G/A polymorphism for A allele versus G allele were built to search for any evidence of publication bias. An assymetric funnel plot is indicative of publication bias, whereas a symmetric funnel plot implies the absence of publication bias. Egger's test, estimated by MIX 1.7 software (Kitasato Clinical Research Center, Kitasato University, Japan), was performed to measure funnel plot asymmetry.

Results {#s3}
=======

Characteristics of eligible studies {#s3.1}
-----------------------------------

The flow diagram illustrates the main reasons for study exclusion ([Figure 1](#pone-0080396-g001){ref-type="fig"}). The selected study characteristics are summarized in [Tables 1](#pone-0080396-t001){ref-type="table"} and [2](#pone-0080396-t002){ref-type="table"}. Thirty-four relevant case--control studies concerning the 1772 C/T and 1790 G/A polymorphisms and cancer risk were included in the meta-analysis. Of the 34 studies, 5 concentrated on prostate cancer \[[@B13]--[@B17]\], 5 on breast cancer \[[@B18]--[@B22]\], 4 on colorectal cancer \[[@B23]--[@B26]\], 3 on oral cancer \[[@B27]--[@B29]\], 3 on lung cancer \[[@B30]--[@B32]\], 2 on pancreatic cancer \[[@B33],[@B34]\], 2 on renal cell carcinoma \[[@B35],[@B36]\], 2 on cervical cancer \[[@B37],[@B38]\], 1 on ovarian cancer, endometrial cancer, and cervical cancer \[39\], and 7 concentrated separately on esophageal squamous cell carcinoma \[[@B40]\], endometrial cancer \[[@B9]\], liver cancer \[[@B41]\], gastric cancer \[[@B42]\], glioma \[[@B43]\], bladder cancer \[[@B44]\], and head and neck squamous cell carcinoma \[[@B8]\]. Among the eligible studies, 34 presented data on 1772 C/T polymorphism and 24 presented data on 1790 G/A polymorphism. For the 1772 C/T polymorphism, the distribution of the genotypes in the control groups in 5 studies was not in Hardy--Weinberg equilibrium \[[@B9],[@B13],[@B28],[@B35],[@B36]\]. For the 1790 G/A polymorphism, the distribution of the genotypes in the control groups in one study was not in Hardy--Weinberg equilibrium \[[@B36]\]. Among the eligible studies, 1 study provided data on three types of cancer (endometrial cancer, ovarian cancer, and cervical cancer) for both polymorphisms \[[@B39]\].

![Reference search and selection of studies in the meta-analysis.](pone.0080396.g001){#pone-0080396-g001}
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###### Characteristics of eligible studies for the association between the 1772 C/T polymorphism and cancer risk.

  First Author (Reference)      Year   Country       Ethnicity   Control Source      Cancer Type                                 Cases        Controls   HWE                         
  ----------------------------- ------ ------------- ----------- ------------------- ------------------------------------------- ------------ ---------- ------ ------ -------- ---- ----------
  Tanimoto                      2003   Japan         Asian       PB                  Head and neck squamous cell carcinoma       45           10         0      98     12       0    0.545
  Kuwai                         2004   Japan         Asian       PB                  Colorectal cancer                           100          0          0      89     11       0    0.561
  Ling                          2005   China         Asian       PB                  Esophogeal sqaumous cell carcinoma          84           11         0      93     11       0    0.569
  Kim                           2008   Korea         Asian       HB                  Breast cancer                               81           8          1      93     9        0    0.641
  Lee                           2008   Korea         Asian       PB                  Breast cancer                               1207         119        6      1245   123      1    0.25
  Nadaoka                       2008   Japan         Asian       PB                  Transitional cell carcinoma of bladder      197          22         419    42     0.35          
  Chen                          2009   China         Asian       PB                  Oral cancer                                 163          10         1      334    13       0    0.722
  Li                            2009   China         Asian       PB                  Gastric cancer                              83           4          0      93     13       0    0.501
  Naidu                         2009   Malaysia      Asian       PB                  Breast cancer                               294          100        16     222    50       3    0.922
  Chai                          2010   China         Asian       HB                  Cervical cancer                             65           25         7      94     21       2    0.52
  Hsiao                         2010   China         Asian       HB                  Hepatocellular carcinoma                    94           8          0      334    13       0    0.722
  Kang                          2011   Korea         Asian       PB                  Colorectal cancer                           38           12         46     4                    
  Kim                           2011   Korea         Asian       HB                  Cervical cancer                             177          22         0      187    27       0    0.325
  Putra                         2011   Japan         Asian       HB                  Lung cancer                                 74           9          0      98     12       0    0.545
  Wang                          2011   China         Asian       HB                  Pancreatic cancer                           209, (198)   54         0      242    29       0    0.352
  Xu                            2011   China         Asian       HB                  Glioma                                      121          27         2      135    14       1    0.354
  Li                            2012   China         Asian       HB                  Prostate cancer                             612          48         2      659    57       0    0.267
  Clifford                      2001   UK            Caucasian   PB                  Renal cell carcinoma                        30           5          0      110    27       6    0.018
  Ollerenshaw                   2004   UK            Caucasian   PB                  Renal cell carcinoma                        16           54         90     1      90       71   \<0.001,
  Fransen                       2006   Sweden        Caucasian   PB                  Colorectal cancer                           167          28         3      213    43       2    0.916
  Konac                         2007   Turkey        Caucasian   HB                  Endometrial, ovarian, and cervical cancer   48           40         14     68     37       2    0.229
  Orr-Urtreger                  2007   Israel        Caucasian   PB                  Prostate cancer                             287          99         16     217    80       3    0.137
  Horre´e                       2008   Netherlands   Caucasian   PB                  Endometrial cancer                          50           5          3      463    84       12   0.001
  Apaydin                       2008   Turkey        Caucasian   PB                  Breast cancer                               79           21         2      68     29       5    0.415
  Foley                         2009   Ireland       Caucasian   PB                  Prostate cancer                             65           30         0      175    13       0    0.623
  Muñoz-Guerra                  2009   Spain         Caucasian   PB                  Oral cancer                                 57,          6          7      113    27       8    0.001
  Konac                         2009   Turkey        Caucasian   HB                  Lung cancer                                 110,         31         0      111    43       2    0.335
  Knechtel                      2010   Austrila      Caucasian   HB                  Colorectal cancer                           291          77         1773   383    \>0.05        
  Ruiz-Tovar                    2012   Spian         Caucasian   PB                  Pancreatic cancer                           47           1          11     116    28       8    0.002
  Kuo                           2012   China         Caucasian   HB                  Lung cancer                                 153          94         38     216    73       11   0.132
  Alves                         2012   Brazil        Caucasian   PB                  Oral cancer                                 0            1          39     0      85       3    \<0.001
  Zagouri                       2012   Greece        Caucasian   HB                  Breast cancer                               98           15         0      107    17       0    0.413
  Chau                          2005   USA           Mixed       PB                  Prostate cancer                             161          29         6      179    14       3    \<0.001
  Li                            2007   USA           Mixed       PB                  Prostate cancer                             818          209        14     175    13       0    0.623

10.1371/journal.pone.0080396.t002

###### Characteristics of eligible studies for the association between the 1790 A/G polymorphism and cancer risk.

  First Author (Reference)      Year   Country    Ethnicity   Control Source      Cancer Type                                 Cases   Controls   HWE                         
  ----------------------------- ------ ---------- ----------- ------------------- ------------------------------------------- ------- ---------- ------ ------ -------- ---- ---------
  Tanimoto                      2003   Japan      Asian       PB                  Head and neck squamous cell carcinoma       51      4          0      101    9        0    0.655
  Kim                           2008   Korea      Asian       HB                  Breast cancer                               87      3          0      94     7        1    0.06
  Nadaoka                       2008   Japan      Asian       PB                  Transitional cell carcinoma of bladder      204     15         421    40     0.25          
  Chen                          2009   China      Asian       PB                  Oral cancer                                 333     14         0      153    20       1    0.697
  Li                            2009   China      Asian       PB                  Gastric cancer                              74      13         0      100    6        0    0.764
  Naidu                         2009   Malaysia   Asian       PB                  Breast cancer                               332     72         6      232    41       2    0.898
  Hsiao                         2010   China      Asian       HB                  Hepatocellular carcinoma                    27      8          0      200    7        0    0.805
  Kim                           2011   Korea      Asian       HB                  Cervical cancer                             187     12         0      200    13       1    0.136
  Putra                         2011   Japan      Asian       HB                  Lung cancer                                 72      9          2      101    9        0    0.655
  Wang                          2011   China      Asian       HB                  Pancreatic cancer                           198     64         1      249    22       0    0.486
  Li                            2012   China      Asian       HB                  Prostate cancer                             614     47         1      685    31       0    0.554
  Clifford                      2001   UK         Caucasian   PB                  Renal cell carcinoma                        35      0          0      140    4        0    0.866
  Ollerenshaw                   2004   UK         Caucasian   PB                  Renal cell carcinoma                        65      67         14     239    39       10   \<0.001
  Fransen                       2006   Sweden     Caucasian   PB                  Colorectal cancer                           189     89         0      247    9        0    0.775
  Konac                         2007   Turkey     Caucasian   HB                  Endometrial, ovarian, and cervical cancer   100     2          0      107    0        0    1
  Orr-Urtreger                  2007   Israel     Caucasian   PB                  Prostate cancer                             198     2          0      298    2        0    0.954
  Apaydin                       2008   Turkey     Caucasian   PB                  Breast cancer                               102     0          0      94     4        0    0.837
  Muñoz-Guerra                  2009   Spain      Caucasian   PB                  Oral cancer                                 40      21         3      130    9        0    0.693
  Konac                         2009   Turkey     Caucasian   HB                  Lung cancer                                 140     1          0      152    2        0    0.936
  Knechtel                      2010   Austrila   Caucasian   HB                  Colorectal cancer                           356     11         2080   76     \>0.05        
  Ruiz-Tovar                    2012   Spian      Caucasian   PB                  Pancreatic cancer                           54      2          3      142    10       0    0.675
  Kuo                           2012   China      Caucasian   HB                  Lung cancer                                 150     1          41     215    74       11   0.154
  Alves                         2012   Brazil     Caucasian   PB                  Oral cancer                                 2       1          37     81     7        0    0.698
  Li                            2007   USA        Mixed       PB                  Prostate cancer                             1053    13         0      1247   17       0    0.81

Summary statistics {#s3.2}
------------------

The meta-analysis for the HIF-1α 1772 C/T polymorphism included 7522 cases and 9847 controls. The prevalence of the CC genotype was the highest, allele C was the most frequent, and the prevalence of the TT genotype was the lowest in both case and control groups.

The meta-analysis for the HIF-1α 1790 G/A polymorphism included 4884 cancer cases and 8154 controls. The prevalence of the GG genotype was the highest, allele G was the most frequent, and the prevalence of the AA genotype was the lowest in both case and control groups.

Overall analysis {#s3.3}
----------------

Upon pooling of all eligible studies, we observed that both 1772 C/T and 1790 G/A polymorphisms were significantly associated with cancer risk in homozygote comparison (1772C/T: TT vs. CC: OR=2.45, 95% CI: 1.52, 3.96; *P* ~heterogeneity~ = 0.028; 1790G/A: AA vs. GG: OR = 4.74, 95% CI: 1.78, 12.6; *P* ~heterogeneity~ \< 0.01), dominant model (1772C/T: TT/CT vs. CC: OR=1.27, 95% CI: 1.04, 1.55; *P* ~heterogeneity~ \< 0.01, 1790G/A: AA/GA vs. GG: OR = 1.65, 95% CI: 1.05, 2.60; *P* ~heterogeneity~ \< 0.01) ([Figures 2](#pone-0080396-g002){ref-type="fig"} and [3](#pone-0080396-g003){ref-type="fig"}), recessive model (1772C/T: TT vs. CC/CT: OR = 3.18, 95% CI: 1.92, 5.29; *P* ~heterogeneity~ \< 0.01, 1790G/A: AA vs. GG/GA: OR = 4.39, 95% CI: 1.61,11.9; *P* ~heterogeneity~ \< 0.01), T allele versus C allele (T vs. C: OR = 1.42, 95% CI: 1.18, 1.70; *P* ~heterogeneity~ \< 0.01), and A allele versus G allele (A vs. G: OR = 1.83, 95% CI: 1.13,2.96; *P* ~heterogeneity~ \< 0.01) ([Figures 4](#pone-0080396-g004){ref-type="fig"} and [5](#pone-0080396-g005){ref-type="fig"}). The association strength between HIF-1α polymorphism and cancer risk is shown in [Table 3](#pone-0080396-t003){ref-type="table"}. No significant association was found in heterozygote comparison (1772C/T: CT vs. CC: OR = 1.15, 95% CI: 0.92, 1.45; *P* ~heterogeneity~ \< 0.01, 1790G/A: GA vs. GG: OR = 1.35, 95% CI: 0.82, 2.21; *P* ~heterogeneity~ \< 0.01). However, the 1772C/T polymorphism was significantly associated with cancer in the heterozygote model (CT vs. CC: OR = 1.29, 95% CI: 1.04, 1.62; P~heterogeneity~ \< 0.01) when studies not in the Hardy--Weinberg equilibrium were excluded.

![Forest plot of dominant model for overall comparison (1772 C/T, **TT**/**CT** vs. CC).](pone.0080396.g002){#pone-0080396-g002}

![Forest plot of dominant model for overall comparison (1790 G/A, **AA**/**GA** vs. GG).](pone.0080396.g003){#pone-0080396-g003}

![Forest plot of overall comparison (1772 C/T, T allele vs. C allele).](pone.0080396.g004){#pone-0080396-g004}

![Forest plot of overall comparison (1790 G/A, A allele vs. G allele).](pone.0080396.g005){#pone-0080396-g005}
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###### Main results of the meta-analysis for the association of HIF1A gene 1772 C/T and 1790 G/A polymorphisms with cancer risk.

  1772 C/T polymorphisms (rs11549465)   TT VS CC   CT VS CC      TT/CT VS CC                               TT VS CT/CC   T allele VS C allele                                                                                                                                                                                  
  ------------------------------------- ---------- ------------- ----------------------------------------- ------------- ----------------------------------------- --------- ----------------------------------------- --------- ----------------------------------------- --------- ----------------------------------------- -------------
  Total                                 34         7522          **2.45 (1.52--3.96)**                     0.028         1.15 (0.92--1.45)                         \<0.001   **1.27 (1.05--1.55)**                     \<0.001   **3.18 (1.92--5.29)**                     \<0.001   **1.42 (1.18--1.70)**                     \<0.001
  Total in HWE                          25         6575          **3.65 (2.47--5.40)**                     0.318         **1.29 (1.04--1.62)**                     \<0.001   **1.35 (1.10--1.65)**                     \<0.001   **3.38 (2.29--5.00)**                     0.476     **1.40 (1.15--1.71)**                     \<0.001
  Cancer types                                                                                                                                                                                                                                                                                                                 
  Breast cancer                         5          2047          **2.30 (1.08--4.91)**                     0.084         1.07 (0.88--1.29)                         0.188     1.12 (0.92--1.35)                         0.711     **2.27 (1.06--4.87)**                     0.120     1.09 (0.76--1.55)                         0.022
  Lung cancer                           3          509           1.41 (0.07--30.4)                         0.044         1.13 (0.59--2.19)                         0.018     **1.50 (1.15--1.96)**                     0.688     **3.27 (1.73--6.17)**                     0.065     1.19 (0.50--2.86)                         \<0.001
  Oral cancer                           3          284           2.01 (0.75--5.41)                         0.463         0.85 (0.24--2.97)                         0.047     1.04 (0.61--1.78)                         0.823     22.8 (0.28--1888)                         \<0.001   3.93 (0.61--25.4)                         \<0.001
  Colorectal cancer                     4          627           1.91 (0.32--11.6)                                       0.24 (0.01--5.51)                         0.027     1.10 (0.87--1.38)                         0.744     1.97 (0.33--11.9)                                   1.36 (0.68--2.70)                         0.002
  Prostate cancer                       5          2396          **3.68 (1.58--8.55)**                     0.871         **2.02 (1.01--4.07)**                     \<0.001   **2.10 (1.08--4.09)**                     0.028     **3.52 (1.52--8.16)**                     0.847     **2.06 (1.15--3.68)**                     \<0.001
  Cervical cancer                       3          328           **10.1 (3.12--32.6)**                     0.153         1.37 (0.92--2.02)                         0.099     **1.63 (1.12--2.37)**                     0.158     **8.26 (2.64--25.9)**                     0.236     1.89 (0.84--4.26)                         0.002
  Others                                13         1331          1.68 (0.42--6.80)                         \<0.001       0.97 (0.56--1.68)                         \<0.001   1.20 (0.98--1.47)                         0.512     **1.99 (1.40--2.84)**                     0.100     1.37 (0.96--1.97)                         \<0.001
  Ethnicities                                                                                                                                                                                                                                                                                                                  
  Caucasian                             15         2151          1.70 (0.81--3.55)                         0.001         0.86 (0.57--1.31)                         \<0.001   1.05 (0.76--1.46)                         \<0.001   **2.97 (1.44--6.14)**                     \<0.001   1.32 (0.99--1.75)                         \<0.001
  Asian                                 17         4134          **4.42 (2.07--9.43)**                     0.997         1.25 (0.98--1.60)                         0.010     **1.33 (1.06--1.68)**                     0.006     **4.12 (1.93--8.77)**                     0.955     **1.40 (1.11--1.78)**                     **0.002**
  Mixed                                 2          1237          3.13 (0.90--10.8)                         0.500         **2.98 (1.92--4.63)**                     0.372     **3.05 (2.00--4.66)**                     0.269     2.77 (0.80--9.54)                         0.646     **2.91 (1.96--4.32)**                     **0.208**
  Source of control                                                                                                                                                                                                                                                                                                            
  PB                                    21         4944          **1.92 (1.05--3.50)**                     0.037         0.99 (0.69--1.41)                         \<0.001   1.17 (0.87--1.57)                         \<0.001   **3.14 (1.60--6.16)**                     \<0.001   **1.40 (1.06--1.84)**                     **\<0.001**
  HB                                    13         2578          **4.38 (2.64--7.47)**                     0.486         **1.32 (1.13--1.57)**                     0.023     **1.39 (1.09--1.77)**                     0.002     **3.88 (2.32--6.51)**                     0.569     **1.46 (1.16--1.85)**                     **\<0.001**
  1790 G/A polymorphisms (rs11549465)   AA VS GG   GA VS GG      AA/GA VS GG                               AA VS GA/GG   A allele VS G allele                                                                                                                                                                                  
                                        N          Sample size   OR^[a](#ngtab3.1){ref-type="table-fn"}^   *P* ^b^       OR^[a](#ngtab3.1){ref-type="table-fn"}^   *P* ^b^   OR^[a](#ngtab3.1){ref-type="table-fn"}^   *P* ^b^   OR^[a](#ngtab3.1){ref-type="table-fn"}^   *P* ^b^   OR^[a](#ngtab3.1){ref-type="table-fn"}^   *P* ^b^
  Total                                 24         5136          **4.74 (1.78--12.6)**                     0.002         1.35 (0.82--2.21)                         \<0.001   **1.65 (1.05--2.60)**                     \<0.001   **4.39 (1.61--11.9)**                     0.001     **1.83 (1.13--2.96)**                     **\<0.001**
  Total in HWE                          23         5090          **4.68 (1.34--16.3)**                     0.001         1.23 (0.77--1.98)                         \<0.001   1.53 (0.99--2.36)                         \<0.001   **4.65 (1.35--16.0)**                     0.001     **1.83 (1.13--2.96)**                     \<0.001
  Cancer types                                                                                                                                                                                                                                                                                                                 
  Breast cancer                         3          521           1.44 (0.38--5.44)                         0.336         1.03 (0.70--1.52)                         0.115     1.05 (0.72--1.53)                         0.077     1.41 (0.37-5.37)                          0.356     1.07 (0.75-1.52)                          0.055
  Lung cancer                           3          362           5.42 (2.75--10.7)                         0.866         0.26 (0.01--7.10)                         \<0.001   0.82 (0.56--1.19)                         0.226     **7.11 (3.61--14.0)**                     0.975     **1.48 (1.09-2.00)**                      0.575
  Oral cancer                           3          375           20.7(0.10--4519)                          \<0.001       2.21 (0.18--26.9)                         \<0.001   7.81 (0.27--224)                          \<0.001   17.5 (0.10--3257)                         \<0.001   9.34 (0.23-388)                           \<0.001
  Prostate cancer                       3          1865          3.35 (0.14--82.3)                                       1.41 (0.97--2.07)                         0.365     1.44 (0.98--2.10)                         0.340     3.25 (0.13--79.9)                                   **1.45 (1.00-2.11)**                      0.330
  Others                                14         1542          **4.81 (2.34--9.87)**                     0.460         1.70 (0.99--2.90)                         \<0.001   1.80 (0.99--3.26)                         \<0.001   **3.01 (1.47--6.21)**                     0.367     **1.91 (1.01-3.58)**                      \<0.001
  Ethnicities                                                                                                                                                                                                                                                                                                                  
  Caucasian                             12         1635          **17.4 (4.01-75.3)**                      0.001         1.09 (0.33--3.58)                         \<0.001   2.19 (0.90--5.34)                         \<0.001   **15.8(3.42--72.9)**                      \<0.001   2.27 (0.92-5.58)                          \<0.001
  Asian                                 11         2435          1.44 (0.60-3.46)                          0.522         1.45 (0.85--2.46)                         \<0.001   1.36 (0.83--2.24)                         \<0.001   1.41 (0.58--3.39)                         0.508     1.42 (0.84-2.40)                          \<0.001
  Source of control                                                                                                                                                                                                                                                                                                            
  PB                                    14         3013          **9.69 (1.41-66.7)**                      \<0.001       1.40 (0.71--2.74)                         \<0.001   1.80 (0.89--3.64)                         \<0.001   **8.08 (1.12--58.1)**                     \<0.001   2.10 (0.95-4.68)                          \<0.001
  HB                                    10         2123          **4.08 (2.26-7.37)**                      0.401         1.23 (0.53--2.86)                         \<0.001   1.47 (0.85--2.55)                         \<0.001   **5.02 (2.79--9.02)**                     0.278     1.50 (0.86-2.62)                          \<0.001

^a^ Random-effects model was used when the *P* value for the heterogeneity test was \< 0.05; otherwise, fixed-effects model was used.

^b^ *P* Value of Q-Test for the Heterogeneity Test

N: number of studies included; OR: odds ratio; PB: population-based; HB: hospital-based; HWE= Hardy--Weinberg equilibrium.

One study contained detailed data on ovarian cancer, endometrial cancer, and cervical cancer. We used the combined data for the overall analysis and the separate data for the subgroup analysis by cancer type.

Subgroup analyses {#s3.4}
-----------------

Subgroup analyses were performed to investigate the effect of cancer type, ethnicity, and source of control. For cancer type, the 1772C/T polymorphism demonstrated an increased risk for breast cancer, lung cancer, prostate cancer, cervical cancer, and other cancers in various models. In the subgroup analyses of "oral cancer" and "colorectal cancer," we did not find any significant association between the 1772C/T polymorphism and cancer risk. The 1790G/A polymorphism exhibited an increased cancer risk for lung cancer in the homozygote and recessive models (AA vs. GG: OR = 5.42, 95% CI: 2.75, 10.7; *P* ~heterogeneity~ = 0.866; AA vs. GG/GA: OR = 7.11, 95% CI: 3.61, 14.0; *P* ~heterogeneity~ = 0.975; A vs. G: OR = 1.48, 95% CI: 1.09, 2.00; *P* ~heterogeneity~ = 0.575) and for prostate cancer (A vs. G: OR = 1.45, 95% CI: 1.00, 2.11; *P* ~heterogeneity~ = 0.330). We found a significant association between 1772C/T and 1790G/A polymorphisms and cancer risk in both population-based and hospital-based studies.

However, ethnicity significantly affected cancer susceptibility. For the 1772C/T polymorphism, a significantly increased cancer risk was found in both Asians and Caucasians. For the 1790G/A polymorphism, a significantly increased cancer risk was found in Caucasians in the heterozygote comparison (AA vs. GG: OR = 17.4, 95% CI: 4.01, 75.3; *P* ~heterogeneity~ \< 0.01) and recessive model (GG/GA: OR = 15.8, 95% CI: 3.42, 72.9; *P* ~heterogeneity~ \< 0.01). However, no significant association between these polymorphisms and cancer risk was found in Asians. These results revealed that the effect of HIF-1α polymorphisms on cancer was associated with ethnicity.

Sensitivity analysis {#s3.5}
--------------------

Sensitivity analysis was performed to explore the influence of an individual study on the pooled results by deleting a single study each time from the pooled analysis. The results showed that no individual study significantly affected the pooled OR because no substantial change was found (figure not shown).

Publication bias {#s3.6}
----------------

Publication bias was assessed by Begg's funnel plot and Egger's test. Begg's funnel plot for the 1772 C/T polymorphism is shown in [Figure 6](#pone-0080396-g006){ref-type="fig"} (*P* = 0.589 for T allele vs. C allele). Egger's test was performed for statistical analysis, and no publication bias was detected (*P* =0.481 for T allele vs. C allele). The results of Begg's and Egger's tests for the 1790 G/A polymorphism were *P* = 0.785 and *P* = 0.870, respectively, for A allele versus G allele ([Figure 7](#pone-0080396-g007){ref-type="fig"}). Overall, no publication bias was detected in the data.

![Funnel plot of heterozygote comparison (1772 C/T, T allele vs. C allele).](pone.0080396.g006){#pone-0080396-g006}

![Funnel plot of heterozygote comparison (1790 G/A, A allele vs. G allele).](pone.0080396.g007){#pone-0080396-g007}

Discussion {#s4}
==========

HIF-1 has an important function in cancer progression and metastasis by activating various genes that are linked to the regulation of angiogenesis, cell survival, and energy metabolism \[[@B3]\]. The presence of T and A variant alleles of HIF-1α 1772, namely, C/T and 1790 G/A polymorphisms, are associated with high transcriptional abilities and protein synthesis in vitro \[[@B8]\]. In vivo studies related these genetic variations to many aggressive clinical features of cancer, such as the ulcerative growth pattern in colorectal tumors, suggesting that HIF-1α polymorphism is associated with cancer \[[@B45]\]. However, studies on the association of HIF-1α 1772 C/T and 1790 G/A polymorphisms with cancer are conflicting. In 2009, Zhao \[[@B10]\] conducted a meta-analysis using 16 case--control studies and concluded that 1772 C/T is significantly associated with higher cancer risk and that 1790 G/A is only significantly associated with breast cancer. Liu \[[@B12]\] performed a similar meta-analysis from 22 case--control studies, including 5552 cases and 8044 controls for 1772 C/T and 3381 cases and 5830 controls for 1790 G/A, and one study evaluated cancer prognosis by polymorphism \[[@B45]\]. This previous study concluded that the 1790 G/A polymorphism and not the 1772 C/T polymorphism is significantly associated with cancer risk. In the present study, we performed an updated meta-analysis from 34 case--control studies that involved 7522 cases and 9847 controls for 1772 C/T polymorphism and 4884 cases and 8154 controls for 1790 G/A polymorphism.

In the present meta-analysis, we investigated the association of HIF-1α 1772 C/T and 1790 G/A polymorphisms with cancer risk. Subgroup analyses by cancer type and ethnicity were also performed. Our analyses showed that both 1772C/T and 1790G/A polymorphisms were significantly associated with cancer risk. In the subgroup study, various types of cancers, such as breast cancer, lung cancer, prostate cancer, and cervical cancer, were associated with 1772C/T, whereas only lung cancer was linked with 1790G/A. However, the odds ratio values in some of the subgroup analyses were large and lacked statistical power because of the significant heterogeneity. Ethnicity may also significantly affect cancer susceptibility. For the 1790G/A polymorphism, we did not find any association between the 1790G/A polymorphism and cancer risk in Asians. This finding can be explained by the difference in genetic background, environmental exposure, and risk factors relating to lifestyle between Asian and Caucasian populations.

Some limitations of this meta-analysis should be addressed. First, the lack of the the detailed information about environment risk factors for cancer risk from included studies limited our further evaluation of potential gene--gene and gene--environment interactions. Second, the *P* value of the Hardy--Weinberg equilibrium of three included studies was less than 0.05, suggesting that these study populations were not representative of the broader target population. Despite these limitations, our meta-analysis had some strong advantages. This meta-analysis shed light on the association between HIF-1α polymorphisms and increased risk for various cancers. In addition, the quality of the included studies was satisfactory and met our inclusion criterion. Moreover, substantial numbers of cases and controls were pooled from different studies, which significantly increased the statistical power of the analysis. No publication bias was also found in the collected data.

In summary, this meta-analysis provided insights into the association of HIF-1α 1772 C/T and 1790 G/A gene polymorphisms with cancer risk, supporting the hypothesis that HIF-1α polymorphisms are a susceptibility marker of cancer. However, large sample studies are warranted to validate our findings, especially in some types of cancer, such as breast cancer and cervical cancer. More studies on gene--gene and gene--environment interactions should also be considered in the future to obtain a more comprehensive understanding of the association between HIF-1α polymorphisms and cancer risk.
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